Long-Term Debt: CytomX Therapeutics Inc (CTMX)

Brandmark of CytomX Corp (CTMX)

CytomX Therapeutics (CTMX) maintains a technological moat through molecule structure patents and capital-intensive R&D that shut out smaller competitors. Business resilience relies on adherence to trial schedules and partner tranches, while long-term debt stands at 0.00. The price history on the GURU.Markets platform visualizes these processes as the company scales capital through strategic alliances with market leaders, securing royalties and upfront payments for joint research.

CTMX (CytomX Therapeutics Inc) Company Long-Term Debt history from 07/04/2022 to 10/29/2026

CytomX Therapeutics Inc - analytical breakdowns and key metrics (CTMX)

- current quotes and average value forecast:
Stock Quotes cytomx.com|CTMX - Price Target Chart
- company stock exchange capitalization indicators:
Market Value CytomX Therapeutics|CTMX - Total Company Value
- book capitalization data:
Net Assets per Single Share CytomX Therapeutics|CTMX - Company Book Value|Market-to-Book Ratio cytomx.com|CTMX - Company Total Assets
- debt level and financial liquidity data:
Debt to Capital Ratio CytomX Therapeutics|CTMX - Long-Term Debt to Equity Ratio|Current Liabilities to Capital CytomX Corp|CTMX - Company Total Debt|Debt to Net Assets Ratio CytomX Therapeutics|CTMX - Company Long-Term Debt|Current Liabilities CytomX Therapeutics
Fundamental company valuation:cytomx.com
Core merchandise of CytomX Therapeutics, Inc.

Long-term debt reflects the aggregate volume of multi-year credit obligations aimed at achieving strategic business goals. The daily calculation of this metric eliminates reporting lags, allowing for the precise tracking of debt load dynamics. By analyzing the trend of the issuer's long-term liabilities, an investor assesses the risk of liquidity shortages. For CytomX Therapeutics (CTMX), this indicator is critical due to its dependence on partners and the high risks of failure in clinical trials for targeted antibodies.

Competitors of CytomX Therapeutics (CTMX)

GERN - Company Long-Term Liabilities|NBTX - Company Long-Term Debt|Long-Term Debt Bicycle Therapeutics PLC|perspectivetherapeutics.com (CATX) - Company Long-Term Debt|GNLX (Genelux) - Company Long-Term Debt|Company Long-Term Debt Molecular Partners|Long-Term Debt Oncolytics ONCY|Company Long-Term Debts LSTA|moleculin.com (MBRX) - Long-Term Indebtedness|Galera Therapeutics, Inc. - Company Long-Term Liabilities|Molecular Templates Corporation (MTEM) - Long-Term Debt